



(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 35/02 (2006.01) *C07K 16/46* (2006.01)

(21) International Application Number:

PCT/US2021/013294

(22) International Filing Date:

13 January 2021 (13.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/960,562 13 January 2020 (13.01.2020) US
63/121,633 04 December 2020 (04.12.2020) US

(71) Applicant: **APTEVO RESEARCH AND DEVELOPMENT LLC** [US/US]; 2401 Fourth Avenue, Suite 1050, Seattle, Washington 98121 (US).

(72) Inventors; and

(71) Applicants: **CLAPPER, Jonathan** [US/US]; Aptev Research and Development LLC, 2401 Fourth Avenue, Suite 1050, Seattle, Washington 98121 (US). **BIENVENUE,**

David [US/US]; Aptev Research and Development LLC, 2401 Fourth Avenue, Suite 1050, Seattle, Washington 98121 (US). **STROMATT, Scott** [US/US]; Aptev Research and Development LLC, 2401 Fourth Avenue, Suite 1050, Seattle, Washington 98121 (US). **MCMAHAN, Catherine J.** [US/US]; Aptev Research and Development LLC, 2401 Fourth Avenue, Suite 1050, Seattle, Washington 98121 (US).

(74) Agent: **MCLEOD, Bonnie Weiss et al.**; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: FORMULATIONS FOR PROTEIN THERAPEUTICS




FIG. 2

(57) Abstract: Described herein are compositions comprising protein therapeutics, including multispecific polypeptides and fusion proteins, for intravenous administration. The compositions may comprise, for example, a multispecific protein, a buffer, an excipient, and a surfactant. In some embodiments, the compositions may comprise a multispecific protein, a succinate buffer, sucrose, and polysorbate 80. Also provided herein are clinical methods, including dosing regimens, for administration of the compositions to a subject in need thereof.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))